This manuscript reviews the current information concerning female sexual dysfunction that is relevant to general psychiatric practice.
Method:
Research identified by the key words sexual dysfunction and prevalence, comorbidity, psychiatric drugs, or pharmacotherapy is reviewed.
Results:
Epidemiologic studies indicate that approximately 30% of female subjects between ages 18 and 59 years have sexual complaints of at least 3 months' duration in the past year. A high comorbidity with other psychiatric syndromes exists. Many psychiatric drugs are associated with sexual dysfunction. Drug treatments for female sexual dysfunction are being investigated.
Conclusion:
Knowledge concerning the treatment of female sexual dysfunction is important to the general psychiatric clinician.
GabbardGO. Mind and brain in psychiatric treatment. In: GabbardGO, editor. Treatments of psychiatric disorders. 3rd ed.Washington (DC): American Psychiatric Press; 2001. p 3–20.
2.
MastersWHJohnsonVE. Human sexual response. Boston: Little Brown; 1966.
3.
MastersWHJohnsonVE. Human sexual inadequacy. Boston: Little Brown; 1970.
4.
SegravesRT. Historical and international context of nosology of female sexual disorders. J Sex Marital Ther2001;27:205–8.
5.
SegravesRT. Psychiatric drugs and inhibited female orgasm. J Sex Marital Ther1988;14:202–7.
6.
WyattRJFramDHBuchbinderR.Treatment of intractable narcolepsy with a monoamine oxidase inhibitor. J Clin Psychopharmacol1971; 85:987–91.
7.
KotinJWilbertD.Thioridazine and sexual dysfunction. Am J Psychiatry1976;133:82–5.
8.
ShifrenJLBraunsteinGDSimonJACassonPRBusterJERedmondGP, and others. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med2000;343:682–8.
9.
BassonRMcInnesRSmithMHodgsonGSpainTKoppikerN.Efficacy and safety of sildenafil in estrogenized women with sexual dysfunction. Obstet Gynecol2000;S54.
10.
RosenRBrownCHeimanSLeiblumSMestonCShabsighRFergusonDD'AgostinoR.The Female Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther2000;26:191–208.
11.
McGahueyCAGelenburgAJLaukesCAMorenoFADelgadoPLMcKnightKM, and others. The Arizona Sexual Experience Scale (ASEX): Reliability and validity. J Sex Marital Ther2000;27:25–40.
12.
LabrieF.Androgen deficiency syndrome in women: Role of androgens and their precursor DHEA in women. Paper presented at the Female Sexual Function Forum; October, 2001; Boston (MA).
13.
GuayAT. Serum androgen and androgen precursor hormone levels in women with and without sexual dysfunction. Paper presented at the Female Sexual Function Forum; October, 2001; Boston (MA).
14.
PlautSM. New diagnostic categories for female sexual dysfunction: Does the falling tree make a sound if no one is there to hear it?J Sex Marital Ther2001;27:193–6.
15.
VroegeJAGijsLHengeveldMW. Classification of sexual dysfunctions in women. J Sex Marital Ther2001;27:237–44.
16.
BassonRBermanJBurnettADerogatisLFergusinDFourcroyJ, and others. Report of the International Consensus Development Conference on female sexual dysfunction: Definitions and classifications. J Sex Marital Ther2001;27:83–94.
17.
LaumannEOGagnonJHMichaelRTMichaelsS.The social organization of sexuality: Sexual practices in the United States. Chicago: University of Chicago Press; 1994.
18.
LaumannEOPaikARosenRC. Sexual dysfunction in the United States: Prevalence and predictors. JAMA1999;281:537–44.
19.
DunnKM. Association of sexual problems with social, psychological, and physical problems in men and women: A cross sectional survey. J Epidemiol Community Health1999;53:144–8.
20.
DunnKM. Satisfaction in the sex life of a general population sample. J Sex Marital Ther2000;26:141–51.
21.
Fugl-MeyerKS. Epidemiology of female sexual function. Paper presented at Female Sexual Function Forum; October, 2001; Boston (MA).
22.
SegravesKBSegravesRT. Hypoactive sexual desire disorder: Prevalence and comorbidity in 906 patients. J Sex Marital Ther1991;17:1–9.
23.
LindalEStefanssonJG. The lifetime prevalence of psychosocial dysfunction among 55- to 57-year olds in Iceland. Soc Psychiatry Psychiatr Epidemiol1993;28:91–5.
24.
GoodwinFKJamisonKR. Manic depressive illness. New York: Oxford University Press; 1990.
25.
LyketsosGCSakkaPMailisA.The sexual adjustment of chronic schizophrenics: A preliminary study. Br J Psychiatry1983;143:376–82.
26.
MillerLJFinnertyM.Sexuality, pregnancy and childrearing among women with schizophrenia-spectrum disorders. Psychiatr Serv1996;47:502–6.
27.
GiftTEWynnneLCHarderD.Sexual life events and schizophrenia. Compr Psychiatry1988;29:151–6.
28.
AizenbergDSiglerMZemishlanyZWeizmanA.Lithium and male sexual function in affective patients. Clin Neuropharmacol1996; 19:515–9.
29.
KockottGPfeifferW.Sexual disorders in nonacute psychiatric outpatients. Compr Psychiatry1996;37:56–61.
30.
RabochJSFaltusF.Sexuality of women with anorexia nervosa. Acta Psychiatr Scand1991;84:9–11.
31.
MorganJFLaceyJHReidF.Anorexia nervosa: Changes in sexuality during weight restoration. Psychosom Med1999;61:541–5.
32.
WiedermanMWPryorTMorganCD. The sexual experience of women diagnosed with anorexia nervosa and bulimia nervosa. Int J Eat Disord1996;19:109–18.
33.
MinnenAVKampmanM.The interaction between anxiety and sexual functioning: A controlled study of sexual functioning in women with anxiety disorders. Sexual and Relationship Therapy2000;15:47–57.
34.
MathewRWeinmanM.Sexual dysfunction without tricyclics in depression. Arch Sex Behav1982;11:323–8.
35.
KennedySHDickensSEEisfeldBSBagbyRM. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord1999;56:210–18.
36.
KivelaSLPahkalaK.Clinician-rated symptoms and signs of depression in aged Finns. Int J Soc Psychiatry1988;34:274–84.
37.
KivelaSLPahkalaK.Symptoms of depression in old people in Finland. Zeitschrift fur Gerontologie1988;21:257–63.
38.
Schreiner-EngelPSchiaviR.Lifetime psychopathology in individuals with low sexual desire. J Nerv Ment Dis1986;174:646–51.
39.
SegravesRT. Sexual side effects of psychotropic agents. In: HalarisA, editor. Bailliere's Clinical Psychiatry. London: WB Saunders; 1997. p 153–70.
40.
SegravesRT. Psychiatric drugs and orgasm in the human female. J Psychosom Obstet Gynec1985;4:125–8.
41.
SegravesRTKavoussiRHughesABateySJohnstonDonahueR, and others. Evaluation of sexual functioning in depressed outpatients: A double blind comparison of sustained release bupropion and sertraline treatment. J Clin Psychopharmacol2000;20:122–6.
42.
NkanginiemeISegravesRT. Neuropsychiatric aspects of sexual disorders. In: FogelB, editor. Neuropsychiatry. Baltimore: Williams and Wilkins; Forthcoming.
43.
RileyARileyE.The effect of single dose diazepam on sexual response induced by masturbation. Sex Martial Therapy1986;1:49–53.
44.
SegravesRT. The effects of minor tranquilizers, mood stabilizers and antipsychotics on sexual function. Primary Psychiatry1999;6:37–40.
45.
HarrisonWRabkinJErhardtAStewartJMcGrathPQuitkinE.Effect of antidepressant medication on sexual function: A controlled study. J Clin Psychopharmacol1986;6:144–9.
46.
MonteiroWNoshirvaniHMarksILelliottP.Anorgasmia from clomipramine in obsessive compulsive disorder: A controlled trial. Br J Psychiatry1987;151:107–12.
47.
ZajeckaJMitchellSFawsettJ.Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. Psychopharmacol Bull1997;33:755–60.
48.
LabbateLAGrimesJHinesAOleshanskyMAAranaG.Sexual dysfunction induced by serotonin reuptake antidepressants. J Sex Marital Ther1998;24:3–12.
49.
ShenWWHsuJH. Female sexual side effects with selective serotonin reuptake inhibitors: A descriptive clinical study of 33 patients. Int J Psychiatry Med1995;25;239–48.
50.
MontejoAILlorcaGIzquierdoJALedesmaABousonoMCalcedoA, and others. SSRI-induced sexual dysfunction. Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter and descriptive clinical study of 344 patients J Sex Marital Ther1997;23:176–94.
51.
WaldingerMDHengeveldMWZwindermanAHOlivierB.Effect of SSRI antidepressants on ejaculation: A double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine and sertraline. J Clin Psychopharmacol1998;18:274–81.
52.
KennedySHEisfeldBSDickensSEBacchiochiJRBagbyRM. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry2000;61:276–81.
53.
FarahA.Relief of SSRI-induced sexual dysfunction with mirtazapine treatment. J Clin Psychiatry1999;60:260–1.
54.
ClaytonALeadbetterRBassKBolden-WatsonCDonahueRJamersonB, and others. Antidepressant-associated sexual dysfunction: Risk factors. Poster presentation at New Clinical Drug Evaluation Unit; May, 1999; Boca Raton (FL).
55.
FergusonJMShrivastavaRKStahlSMHartfordJTBorianFIeniJ, and others. Reemergence of sexual dysfunction in patients with MDD: Double-blind comparison of nefazodone and sertraline. J Clin Psychiatry2001;62:24–9.
56.
CroftHSettleEHouserTBateySDonahueRAscherJ.A placebo-controlled comparison of the antidepressant and sexual functioning aspect of bupropion sustained release and sertraline. Clin Ther1999;21:643–58.
57.
SegravesRTCroftHKavoussiRAscherJBateySFosterV, and others. Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women. J Sex Marital Ther2001;27:303–16.
58.
WalkerPWColeJGardnerEHughesAJohnstonABateyS, and others. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry1993;54:459–65.
59.
ClaytonDOShenWW. Psychotrophic drug-induced sexual function disorders. Drug Safety1998;19:299–312.
60.
RosenRCLaneRMMenzaM.Effects of SSRIs on sexual function: A critical review. J Clin Psychopharmacol1999;19:67–85.
61.
AizenbergDNoarSZemishlanyZWeizmanA.The serotonin antagonist mianserin for treatment of serotonin reuptake inhibitor induced sexual dysfunction in women: An open label add on trial. Clin Neuropharmacol1999;22:347–50.
62.
BalonR.Fluoxetine-induced sexual dysfunction and yohimbine. J Clin Psychiatry1993;54:161.
63.
ShrivastavaRShrivastavaSOverwegN.Amantadine in the treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors. J Clin Psychiatry1995;15:83–4.
64.
RileyARileyE.Cyproheptadine and antidepressant-induced anorgasmia. Br J Psychiatry1986;148:217–8.
65.
GitlinMJ. Treatment of sexual side-effects with dopaminergic agents. J Clin Psychiatry1995;56:124.
66.
PiesR.Safety of sildenafil for antidepressant related sexual dysfunction. J Clin Psychiatry1999;60:792.
67.
BerkM.Serotonergic targets in the treatment of antidepressant induced sexual dysfunction: A pilot study of grnaisetron and sumatriptan. Int Clin Psychopharmacol2000;15:291–5.
68.
NordenMJ. Buspirone treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors. Depression1994;2:109–12.
69.
AshtonARosenR.Bupropion as an antidote for serotonin reuptake inhibitor induced sexual dysfunction. J Clin Psychiatry1998;59:112–5.
70.
NelsonEB. A placebo-controlled crossover trial of granisetron in SRI- induced sexual dysfunction. J Clin Psychiatry2001;62:469–73.
71.
ClaytonAMcGarveyELWarncokJKornsteinSPinkertonRC. Poster presentation at New Clinical Drug Evaluation Unit; May, 1999; Boca Raton (FL).
72.
MichelsonDBancroftJTargumSKimYTepnerR.Female sexual dysfunction associated with antidepressant administration: A randomized, placebo-controlled study of pharmacologic intervention. Am J Psychiatry, 2000; 157:239–43.
73.
LandenMErikssonEAgrenHFahlenT.Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol1999;19:268–71.
74.
NurnbergGLaurielloJHensleyPParkerLKeithS.Sildenafil for iatrogenic serotonergic antidepressant medication-induced sexual dysfunction in four patients. J Clin Psychiatry1999;60:33–5.
75.
BaldwinD.Schizophrenia, antipsychotic drugs and sexual function. Primary Care Psychiatry1997;3:115–23.
76.
ShenWWParkS.Thioridazine induced inhibition of female orgasm. Psychiatry J Univ Ottawa1982;7:249–51.
MontejoALlorcaG.New antipsychotic induced sexual dysfunction: Comparative incidence with risperidone and olanzapine using a questionnaire. American Psychiatric Association, New Research; 1998. p 152–3.
84.
GazzolaLOplerL.Return of menstruation after switching from risperidone to olanzapine. J Clin Psychopharmacol1998;18:486–7.
85.
MarkenPHyakalRFisherJ.Management of psychotropic induced hyperprolactinemia. Clin Pharmacy1992;11:851–6.
86.
TollinS.Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest2000;23:765–70.
87.
IsojarviJRepoMPakarinenALukkarinemOMyllylaVV. Carbamazepine, phenytoin, sex hormones, and sexual function in men with epilepsy. Epilepsia1995;36:366–70.
88.
TieferL.The selling of female sexual dysfunction. J Sex Marital Ther2001;27:625–8.
89.
BartikBGoldbergJ.Female sexual arousal disorder. In: LeiblumSRRosenRC, editors. Principles and practice of sex therapy. New York: Guilford; 2000. p 85–117.
90.
BecherEFBecharaACasabeA.Clitoral hemodynamic changes after a topical application of alprostadil. J Sex Marital Ther2001;27:405–10.
91.
IslamAMitchelJRosenRPhillipsNAyersCFergusonD, and others. Topical alprostadil in the treatment of female sexual arousal disorder: A pilot study. J Sex Marit Ther2001;27:531–40.
92.
BassonR.Female sexual response: The role of drugs in the management of female sexual dysfunction. Obstet Gynecol2001;98:350–3.
93.
CarusoSIntelisanoGLupoLAgnelloC.Premenopausal women affected by sexual arousal disorder treated with sildenafil: A double-blind cross-over placebo-controlled study. British Journal of Obstetrics and Gynecology2001;108:623–8.
94.
BillipsKLBermanLBermanJMetzMGlennonMGoldsteinI.A new non-pharmacological vacuum therapy for female sexual dysfunction. J Sex Marital Ther2001;27:435–42.
95.
SegravesRTCroftHKavoussiRAscherJABateySRFosterVJ, and others. Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women. J Sex Marital Ther2001;27:303–16.
96.
SherwinBB. Use of combined estrogen-androgen preparations in the postmenopause: Evidence from clinical studies. Int J Fertil Womens Med1998;43:98–103.
97.
ShifrenJBraunsteinGSimonJCassonPBusterJRedmondG, and others. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med2000;343:1–8.
98.
TuitenAVan HonkJKoppeschaarHBernaardsCThijssenJ.Time course of effects of testosterone administration on sexual arousal in women. Arch Gen Psychiatry2000;57:149–53.
